EPO

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	7

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01534182 (ClinicalTrials.gov)	January 2012	8/2/2012	Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transi ...	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcome ...	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Interferon beta - 1a (IFN);Drug: Glatiramer acetate (GA)	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	298	Phase 4	Russian Federation
2	NCT01317004 (ClinicalTrials.gov)	May 2011	15/3/2011	Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcome ...	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Standard MS DMT	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	61	Phase 4	Italy
3	NCT01216072 (ClinicalTrials.gov)	August 2010	7/9/2010	A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FT ...	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutCome ...	Relapsing Forms of Multiple Sclerosis	Drug: Fingolimod;Drug: Standard MS DMTs	Novartis Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	1053	Phase 4	United States;Canada;Puerto Rico
4	EUCTR2009-011516-37-DK (EUCTR)	29/05/2009	15/05/2009	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disabilit ...	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disabilit ...	Multiple Sclerosis, with primary and secondary progressive courses. MedDRA version: 9.1;Level: LLT;C ...	Trade Name: NeoRecormon INN or Proposed INN: Solu-Medrol Other descriptive name: METHYLPREDNISOLONE SO ...	Danish Multiple Sclerosis Research Centre	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
5	EUCTR2008-005125-11-GB (EUCTR)	19/12/2008	07/01/2009	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo ...	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo ...	Primary progressive multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063401;T ...	Trade Name: Neorecormon Product Name: Recombinant Human Erythropoietin Product Code: rhEPO INN or Propo ...	Walton Centre for Neurology and Neurosurgery	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
6	EUCTR2005-005592-14-DE (EUCTR)	27/07/2006	12/05/2006	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an ...	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an ...	Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents ...	Trade Name: Erypo/Erypo FS Product Name: Erypo/Erypo FS INN or Proposed INN: Epoetin alfa Other descrip ...	IFSgGmbH, Institute for clinical research	NULL	Not Recruiting			Female: yes Male: yes			Germany
7	NCT00818103 (ClinicalTrials.gov)	January 2006	31/12/2008	Characteristic Study on Chinese Patients With Multiple Sclerosis	Characteristic Study on Chinese Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: atorvastatin;Drug: ß-interferon;Drug: EPO	Sun Yat-sen University	Third Affiliated Hospital, Sun Yat-Sen University	Recruiting	N/A	65 Years	Both	600	N/A	China

First Previous1Next Last